TIDMAGY
RNS Number : 9714G
Allergy Therapeutics PLC
10 March 2015
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS
RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN
WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE
UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH
AFRICA, NEW ZEALAND OR ANY OTHER JURISDICTION IN WHICH SUCH
RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
10 March 2015
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Proposed Placing and Notice of General Meeting
Placing to raise net proceeds of approximately GBP20 million to
be used to fund the clinical development of Pollinex(â) Quattro
Grass through to FDA regulatory approval
Allergy Therapeutics, the fully integrated specialty
pharmaceutical company specialising in allergy vaccines, is pleased
to announce a conditional placing of 94,117,650 Placing Shares at a
price of 22.1 pence per Placing Share to raise up to approximately
GBP20.0 million after expenses.
Highlights
-- 94,117,650 new ordinary shares of 0.1 pence each in the
capital of the Company (the "Placing Shares") conditionally placed
with institutional and other investors to raise proceeds of GBP20.8
million before expenses (the "Placing")
-- Placing price of 22.1 pence per Placing Share (the "Placing
Price"), representing a discount of 10.0 per cent. to the average
mid-market closing price over the previous 60 trading days up to
and including 5 March 2015
-- The net proceeds of the Placing will be used to fund the
clinical development of lead product Pollinex(â) Quattro Grass
through to a BLA to obtain FDA regulatory approval in the US
-- Pollinex Quattro Grass could become the first licensed
seasonal SCIT allergy vaccine authorised for marketing in the US,
with an estimated $2 billion market
-- Current timetable earmarks US Pollinex Quattro Grass launch during 2019
-- Panmure Gordon is acting as Financial Adviser, Nominated
Adviser and sole bookrunner to the Placing
The Placing is conditional, inter alia, on the approval by
Shareholders at a general meeting to be held at 9.30 a.m. on 30
March 2015 at the offices of Covington & Burling LLP, 265
Strand, London WC2R 1BH (the "General Meeting") and on the
Admission of the Placing Shares to trading on AIM.
The Circular to Shareholders, including a notice convening the
General Meeting, will be dispatched shortly and will also be
available on the Company's website at
www.allergytherapeutics.com/.
Manuel Llobet, Chief Executive Officer, said:
"With the funds raised from the Placing, we are now focused on
progressing the clinical development of Pollinex Quattro Grass
through to FDA approval and planned launch in the US in 2019. We
have the opportunity to be the first FDA-licensed seasonal
subcutaneous immunotherapy allergy vaccine, and so access an
estimated $2 billion market. We are confident that the potential
benefits of our treatment, which should result in a safe and
effective vaccine following only an ultra-short dosing schedule,
will be a key differentiator when compared with other treatments
available in the market. This would, in turn, allow us potentially
to bring significant relief to the many moderate to severe grass
allergy patients in the US and thereby enable us to generate
significant value for our shareholders."
+44 (0) 1903 845
Allergy Therapeutics 820
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
+44 (0) 20 7886
Panmure Gordon 2500
Freddy Crossley / Peter Steel / Duncan Monteith,
Corporate Finance
Tom Salvesen, Corporate Broking
+44 (0) 20 3727
FTI Consulting 1000
Simon Conway
Victoria Foster Mitchell
All defined terms used in this announcement are defined in the
appendix to this announcement.
Additional details of the Placing
Introduction
The Company is pleased to announce that it proposes to raise
approximately GBP20.0 million (after expenses) by way of the
Placing with existing and new institutional investors, conducted by
Panmure Gordon. The Company will, pursuant to the Placing, issue
94,117,650 Placing Shares at a Placing Price of 22.1 pence per
share. The Placing is conditional, among other things, upon the
approval of the Resolutions by the Shareholders at the General
Meeting for the purposes of authorising the Directors to allot the
Placing Shares and to disapply statutory pre-emption rights in
relation thereto. The formal Notice of General Meeting is set out
at the end of the Circular.
Background to and reasons for the Placing
Overview
Allergy Therapeutics is a European-based, fully-integrated
specialty pharmaceutical company with a global footprint focused on
the treatment and prevention of allergic rhinitis with aluminium
free immunotherapies. The Company's core strategy is to create a
sustainable, fast-growing and profitable global specialty
pharmaceutical business with a substantial franchise in the allergy
sector through the development of innovative, patented, registered
therapies for both the treatment and prevention of allergy-related
conditions.
Allergy Therapeutics' products are sold into the immunotherapy
sector of the allergy market, which is worth $1.3bn worldwide
(Europe and the US being the main markets), and is forecast to grow
by approximately 90 per cent. between 2015 and 2020 (Visiongain, AR
Forecast 2014), the fastest growth within the allergy market.
Allergy Therapeutics sells an established range of diagnostics
and aluminium-free allergy immunotherapy vaccines primarily in
injectable (subcutaneous) plus oral (sublingual) formats. The
Company's key products include Pollinex Quattro, a proven and
highly differentiated ultrashort SCIT for grass, ragweed and tree
allergy, which accounted for approximately 51 per cent. of the
Group's reported revenues in the year ended 30 June 2014. Pollinex
Quattro was launched in 1999, transforming immunotherapy by
introducing an allergy vaccination with a short treatment period of
only four injections per course. The short treatment period is due
to the use of an improved extract allergen, modified in order to
lower its allergenicity while keeping its immunogenicity, and the
innovative adjuvant MPL, a substance which has been documented to
improve the immune response to an antigen or allergen and to which
Allergy Therapeutics has certain exclusive rights.
The Company has undertaken clinical studies on Pollinex Quattro
Grass, Ragweed and Tree respectively in the US which, in 2007, were
put on clinical hold by the FDA. The clinical hold for Pollinex
Quattro Grass was lifted in August 2012. The FDA has since
confirmed that data from the Phase I, Phase II and Phase III
studies remain valid and sufficient for the purposes of a BLA for
regulatory approval of the product in the US, subject to completion
of the further studies required, as discussed below.
Growth Strategy
The Company's business plan is to build a strong, sound and
profitable European base as the platform for global expansion, in
particular into the US. The Board's strategy to achieve this
objective includes:
-- Accelerating organic growth by leveraging the Company's infrastructure, for example by:
o increasing product penetration and market share in existing
geographies;
o launching existing products into new European markets and
through distribution into selected emerging markets;
o product registration using a mutual recognition process in new
European markets;
o developing enhanced allergy vaccines with improved dosing
characteristics and new delivery formulations; and
o launching new products in areas such as probiotics.
-- As they arise, reviewing inorganic growth opportunities:
o that would augment the Company's existing product portfolio
through new product acquisitions and/or entry into further
in-licensing agreements leveraging the Company's existing routes to
market;
o that would improve margins through synergistic acquisitions,
extending Allergy Therapeutics' vertical integration; and
o that would diversify the Company's activities in the specialty
pharmaceuticals field.
-- Undertaking clinical trials and seeking FDA regulatory
approval for a number of existing products, with primary initial
focus on Pollinex Quattro Grass, to capitalise on opportunities in
the US market, leveraging the significant investment the Company
has already made in research and development to date.
The US Opportunity
It is estimated that US allergy immunotherapy total spend,
including preparation and administration costs, was $2 billion in
2008 (Piper Jaffrey Investment Research), with over 80 million
people in the US having some type of allergy. The main pollen
allergens - grass, ragweed and trees - have prevalence on the
population of approximately 50 per cent., 30 per cent. and 26 per
cent. respectively. The US market, like Germany, is predominately
SCIT focused, but currently has no registered SCIT products.
Following FDA approval, Pollinex Quattro Grass would be the
first licensed seasonal SCIT allergy vaccine authorised for
marketing in the US. The Board believes that the availability of
FDA-approved standard vaccines could potentially grow this market
further due to increasing treatment penetration rates and the
introduction of short course treatments.
The Board is therefore of the view that prospects for Pollinex
Quattro could be significant and transformational for the Company
and, following the anticipated launch in 2019, the Board will set a
target of a substantial share of the estimated $2 billion market
over a four to five year period. To capitalise on the opportunity
in the US market, the Company intends to progress the clinical
development of Pollinex Quattro Grass by way of a further Phase III
study and other related studies. Once complete, this will enable
the submission of a BLA to gain FDA regulatory approval for the
product in the US.
The FDA has agreed in principle the synopses and is now
reviewing the full protocol and statistical analysis to allow the
clinical development to start; this permission is expected to be
granted during March 2015. Based on the clinical development
programme remaining on the Company's anticipated timeline and
subject to the FDA's permission, the Company is seeking to launch
Pollinex Quattro Grass in the US during 2019.
Use of proceeds
The Directors intend that the net proceeds of the Placing, being
approximately GBP20.0 million, will be used by the Company
principally to fund the clinical development of Pollinex Quattro
Grass through to FDA approval by way of a BLA. In particular, the
net proceeds will fund the following key stages of the
programme:
-- undertaking a Safety Study on the planned dosage of Pollinex Quattro Grass;
-- performance of a Pilot Study to select the best cumulative dosage;
-- undertaking an Environmental Exposure Chamber Phase III
Efficacy Study, as required for the BLA; and
-- performance of a Patient Registry Study to provide a safety
data set, as currently required for the BLA.
Following the BLA submission, the Board anticipates that the
remainder of the programme financing requirement will be funded by
the Company's future cash generation.
Results and current trading
The Company announced its unaudited half yearly results for the
six month period ended 31 December 2014 on 2 March 2015 available
on the Company's website at
http://www.allergytherapeutics.com/investor-relations.aspx. As in
previous years, owing to the seasonality of the pollen allergy
market, approximately 60 to 70 per cent. of the Company's revenues
are generated in the first half of the financial year and, as a
consequence, the Company typically records profits in the first
half of the year and losses in the second half. While markets in
Europe are expected to remain flat in the near future, the Company
will continue to drive further market penetration with a portfolio
of short and ultrashort course aluminium free allergy vaccines,
which are increasingly becoming the treatment of choice with
prescribers. The Directors believe that this should allow the
Company to improve margins through leveraging the improved
manufacturing facilities that the Company has put in place, and
remain excited about the prospects for the future.
Details of the Placing
The Company is proposing to raise approximately GBP20.0 million
(after fees and expenses) by way of a conditional, non-pre-emptive
placing of 94,117,650 new Ordinary Shares at the Placing Price. The
Placing Price represents a discount of approximately 10.0 per cent.
to the closing mid-market price over the previous 60 trading days
up to and including 5 March 2015. The Placing Shares will represent
approximately 17.2 per cent. of the Enlarged Issued Share
Capital.
In order to broaden the Company's institutional shareholder base
and to minimise the time and transaction costs of the Placing, the
Placing Shares are only being placed by Panmure Gordon with a
limited number of existing and new institutional shareholders. The
Placing Shares are not being made available to the public.
The Board believes that raising equity finance using the
flexibility provided by a non-pre-emptive placing is the most
appropriate and optimal structure for the Company at this time.
This allows both existing institutional holders and new
institutional investors the opportunity to participate in the
Placing and avoids the requirement for a prospectus, which is a
costly and time-consuming process.
The Placing Agreement
In connection with the Placing, the Company has entered into a
Placing Agreement pursuant to which Panmure Gordon has agreed, in
accordance with its terms, to use reasonable endeavours to procure
subscribers for the Placing Shares at the Placing Price. The
Placing is not underwritten. In accordance with the terms of the
Placing Agreement, the Placing is conditional upon, amongst other
things, the passing of the Resolutions, Admission occurring on 1
April 2015 (or such later date as the Company and Panmure Gordon
may agree, not being later than 15 April 2015). The Placing
Agreement is terminable by Panmure Gordon in certain circumstances
up until the time of Admission
Application will be made to the London Stock Exchange for the
Placing Shares to be admitted to trading on AIM. Subject to the
passing of the Resolutions at the General Meeting, it is expected
that admission to AIM will become effective in respect of, and that
dealings on AIM will commence in, the Placing Shares, on or around
1 April 2015.
The Placing Shares will be issued credited as fully paid and
will be identical to and rank pari passu in all respects with the
Existing Ordinary Shares, including the right to receive all future
distributions declared, paid or made in respect of the Ordinary
Shares following the date of Admission.
Related Party Transaction
Where a company enters into a related party transaction, under
the AIM Rules the independent directors of the company are
required, after consulting with the company's nominated adviser, to
state whether, in their opinion, the transaction is fair and
reasonable in so far as its shareholders are concerned.
As at the date of the Circular, Beagle Partners LLP ("Beagle
Partners") has an interest in 112,289,283 Ordinary Shares (on
behalf of Southern Fox Investments Limited as its investment
manager), representing 27.4 per cent. of the issued share capital
of the Company. Beagle Partners has subscribed GBP2.8 million for
12,669,500 Ordinary Shares in the Placing. The issue of Ordinary
Shares to Beagle Partners constitutes a related party transaction
under Rule 13 of the AIM Rules for Companies.
The Directors, having consulted with Panmure Gordon, the
Company's nominated adviser, consider that the terms of Beagle
Partners' participation in the Placing are fair and reasonable
insofar as the shareholders are concerned.
Convertible Loan Notes
The Convertible Loan Notes are repayable in accordance with
their terms on 31 March 2015. On repayment, CFR International is
required to apply the principal sum repaid of GBP4,042,489 in
subscribing for 41,674,938 Conversion Shares at 9.7 pence per
share. CFR International and Yissum Holding are direct and indirect
wholly owned subsidiaries respectively of CFR Pharmaceuticals. On
26 September 2014, Abbott Laboratories, through a series of
controlled undertakings, acquired a 99.9 per cent. interest in the
shares of CFR Pharmaceuticals. The interests of Abbott Laboratories
(the ultimate owner of CFR International and Yissum Holding) in the
Existing Ordinary Shares and the Enlarged Issued Share Capital are
set out below:
% of % of Enlarged
No. Ordinary Existing No. Placing No. Conversion No. Ordinary Issued
Shares currently Ordinary Shares Shares Shares held Share
held Shares issued issued on Admission Capital
CFR International 61,417,845 14.98% - 41,674,938 103,092,783 18.89%
Yissum Holding 137,491,788 33.54% - - 137,491,788 25.19%
Total: 198,909,633 48.51% - 41,674,938 240,584,571 44.08%
On 30 March 2012, Allergy Therapeutics published a circular (the
"2012 Circular") convening a general meeting held on 19 April 2012
in which Shareholders approved the issue of the Convertible Loan
Notes and a waiver of the obligation that would otherwise arise on
CFR International, pursuant to Rule 9 of the Takeover Code, to make
a general offer to the shareholders of the Company at such time as
the Conversion Shares are issued to CFR International.
At the time of the issue of the Convertible Loan Notes, Manuel
Llobet and Alejandro Weinstein Jr, (Allergy Therapeutics' Chief
Executive Officer and a former non-executive Director of the
Company respectively) were, as described in the 2012 Circular,
deemed to be acting in concert with CFR International, CFR
Pharmaceuticals, Yissum Holding and certain other parties.
Following the sale of the Weinstein Family's controlling interest
in CFR Pharmaceuticals to Abbott Laboratories in September 2014,
Alejandro Weinstein Jr stepped down from the Board on 8 October
2014. As such, Mr Llobet and his associates, being Natacha Olarte,
Joshua Llobet, Antua Llobet and Wild Indigo, are no longer deemed
to be acting in concert with CFR International, CFR Pharmaceuticals
and Yissum Holding.
CFR International and Yissum Holding will, on Admission, be
interested in 240,584,571 Ordinary Shares, representing 44.1 per
cent. of the Company's Enlarged Issued Share Capital. Rule 9 of the
Takeover Code provides that, among other things, where any person
who, together with persons acting in concert with him, is
interested in securities which in aggregate carry not less than 30
per cent. but do not hold shares carrying more than 50 per cent. of
the voting rights of a company which is subject to the Takeover
Code, and such person, or any person acting in concert with him,
acquires an additional interest in securities which increases the
percentage of securities carrying voting rights in which he is
interested, then such person is normally required to make a general
offer to all the holders of any class of equity share capital or
other class of transferable securities carrying voting rights of
that company to acquire the balance of their interests in the
company. An offer under Rule 9 of the Takeover Code must be in cash
(or with a cash alternative) and at the highest price paid within
the preceding 12 months for any shares. On issue of the Conversion
Shares, no such obligations under Rule 9 shall become due.
Application will be made to the London Stock Exchange for the
Conversion Shares to be admitted to trading on AIM and it is
expected that admission will become effective in respect of, and
that dealings on AIM will commence in, the Conversion Shares, on 1
April 2015. The Conversion Shares will be issued credited as fully
paid and will be identical to and rank pari passu in all respects
with the Existing Ordinary Shares, including the right to receive
all future distributions declared, paid or made in respect of the
Ordinary Shares following the date of Admission.
General Meeting
A notice convening a General Meeting of Allergy Therapeutics
plc, to be held at the offices of Covington & Burling LLP, 265
Strand, London WC2R 1BH on 30 March 2015 at 9.30 a.m., for the
purpose of considering and, if thought fit, passing the proposed
resolutions, will be set out at the end of the Circular. At this
meeting, an ordinary resolution will be proposed to authorise the
Directors under section 551 of the Companies Act 2006 to allot
94,117,650 Ordinary Shares and a special resolution will be
proposed to authorise the Directors under section 570 of the
Companies Act 2006 to allot 94,117,650 Ordinary Shares pursuant to
the Placing on a non-pre-emptive basis.
Action to be taken
Shareholders will find enclosed with the Circular a form of
proxy for use at the General Meeting. It is important that you
complete and sign the enclosed form of proxy in accordance with the
instructions printed thereon.
Recommendation by the Directors and Irrevocable Undertakings
The Directors believe that the Placing is in the best interest
of the Company and its Shareholders as a whole. Accordingly, the
Directors unanimously recommend that Shareholders vote in favour of
the Resolutions to be proposed at the General Meeting as the
Directors have irrevocably undertaken to do in respect of their own
beneficial holdings amounting to, in aggregate, 5,381,513 Ordinary
Shares, representing approximately 1.3 per cent. of the Existing
Ordinary Shares.
In addition to the Directors, Abbott Laboratories (on behalf of
CFR International and Yissum Holding) and Beagle Partners (on
behalf of Southern Fox Investments Limited as its investment
manager) have irrevocably undertaken to vote in favour, or procure
the vote in favour, of the Resolutions in respect of the Existing
Ordinary Shares in which they are interested, amounting to
61,417,845 Ordinary Shares, 137,491,788 Ordinary Shares and
112,289,283 Ordinary Shares respectively, representing, in
aggregate, approximately 75.9 per cent. of the Existing Ordinary
Shares.
Panmure Gordon (UK) Limited, which is authorised and regulated
in the United Kingdom by the Financial Conduct Authority, is acting
exclusively for Allergy Therapeutics plc in relation to the
transaction referred to in this announcement. Panmure Gordon (UK)
Limited is not acting for, and will not be responsible to, any
person other than Allergy Therapeutics plc for providing the
protections afforded to customers of Panmure Gordon (UK) Limited or
for advising any other person on the contents of this announcement
or any transaction or arrangement referred to herein. Panmure
Gordon (UK) Limited has not authorised the contents of any part of
this announcement and neither accepts liability whatsoever for the
accuracy of any information or opinion contained in this
announcement or for the omission of any material information from
this announcement for which the Company is responsible. No
representation or warranty, express or implied, is made by Panmure
Gordon (UK) Limited as to any of the contents of this
announcement.
The distribution of this announcement in jurisdictions other
than the United Kingdom may be restricted by law and therefore
persons into whose possession this document and/or accompanying
documents come should inform themselves about and observe any such
restrictions. Any failure to comply with any such restrictions may
constitute a violation of the securities laws or regulations of
such jurisdictions. In particular, subject to certain exceptions,
this announcement should not be distributed, forwarded to or
transmitted in or into the United States (as defined in Regulation
S of the United States Securities Act of 1933, as amended
("Regulation S") or Australia, Canada, Japan, the Republic of South
Africa and New Zealand (the "Excluded Jurisdictions"). None of the
Placing Shares have been, nor will they be, registered in the
United States under the United States Securities Act of 1933 (the
"Securities Act"), as amended, or under the securities laws of any
of the Excluded Jurisdictions and, subject to certain exceptions,
they may not be offered or sold directly or indirectly within or
into the Excluded Jurisdictions or to, or for the account or
benefit of, any national, citizen or resident of the Excluded
Jurisdictions. Subject to certain exceptions, none of the Placing
Shares may be offered or sold, directly or indirectly, in the
United States or to, or for the account or benefit of, U.S. persons
(as such terms are defined in Regulation S under the Securities
Act). This announcement does not constitute an offer to sell or
issue or the solicitation of an offer to buy or subscribe for
Placing Shares in any jurisdiction in which such offer or
solicitation is unlawful.
DEFINITIONS
The following definitions apply throughout this announcement,
unless the context requires otherwise:
Abbott Laboratories Abbott Laboratories
Admission the admission of the Placing Shares and the
Conversion Shares to trading on AIM becoming
effective in accordance with the AIM Rules
AIM the AIM market operated by the London Stock
Exchange
AIM Rules the AIM Rules for Companies published by
the London Stock Exchange
BLA biological licence application
CFR International CFR International SpA, incorporated in Chile
and whose registered number is 76116262-4
and whose registered office address is Pedro
de Valdivia Av. Number 295, Providencia,
city of Santiago, Chile
CFR Pharmaceuticals CFR Pharmaceuticals S.A., incorporated in
Chile and whose registered office address
is de Valdina Av. Number 295, Providencia,
city of Santiago, Chile
Circular a circular to Shareholders to be sent on
10 March 2015, including a notice convening
the General Meeting
Company or Allergy Allergy Therapeutics plc whose registered
Therapeutics number is 05141592 and whose registered office
address is Dominion Way, Worthing, West Sussex
BN14 8SA
Conversion Shares the 41,674,938 new Ordinary Shares to be
issued to CFR International at the issue
price of 9.7 pence per share on redemption
of the Convertible Loan Notes
Convertible Loan Notes the 4,042,469 convertible loan notes of GBP1
each issued pursuant to the Convertible Loan
Note Instrument and held by CFR International
Convertible Loan Note the convertible loan note instrument executed
Instrument by the Company on 30 March 2012, as amended
CREST the relevant system (as defined in the Uncertificated
Securities Regulations 2001) in respect of
which Euroclear UK & Ireland Limited is the
operator (as defined in those regulations)
Directors or the Board the board of directors of the Company as
at the date of this announcement
Enlarged Issued Share the issued ordinary share capital of the
Capital Company immediately following Admission
Euroclear Euroclear UK & Ireland Limited, the operator
of CREST
Existing Ordinary the 410,055,331 Ordinary Shares in issue
Shares at the date of this announcement, all of
which are admitted to trading on AIM
FCA the Financial Conduct Authority
FDA Food and Drug Administration, the US governmental
agency responsible for the evaluation of
medicines
General Meeting the general meeting of the Company convened
for 9.30 a.m. on 30 March 2015 (or any adjournment
thereof), pursuant to the Notice of Meeting
Group the Company and its Subsidiaries
London Stock Exchange London Stock Exchange plc
MPL monophosphoryl-lipid A
Notice of Meeting the notice of the General Meeting
Ordinary Shares ordinary shares of 0.1 pence per share each
in the capital of the Company
Panmure Gordon Panmure Gordon (UK) Limited
Placing the placing of the Placing Shares at the
Placing Price pursuant to the Placing Agreement
Placing Agreement the conditional agreement dated 9 March 2015
and made between Panmure Gordon and the Company
in relation to the Placing
Placing Price 22.1 pence per Placing Share
Placing Shares the 94,117,650 new Ordinary Shares to be
issued pursuant to the Placing
GBP and pence respectively pounds and pence sterling, the
lawful currency of the United Kingdom
Resolutions the resolutions set out in the Notice of
Meeting
SCIT subcutaneous immunotherapy
Shareholder a holder of Ordinary Shares
Subsidiaries the subsidiaries of the Company
Takeover Code the City Code on Takeovers and Mergers
United Kingdom the United Kingdom of Great Britain and Northern
Ireland
US or United States the United States of America, each state
thereof, its territories and possessions,
and all areas subject to its jurisdiction
Yissum Holding Yissum Holding Limited, incorporated in Malta
and whose registered number is C50641 and
whose registered office address is Tower
Business Centre, Level 1, Suite 5, Tower
Street, Swatar, Birkirkara BKR 4013, Malta
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEXKLLBEXFBBBX
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024
